Avidity Biosciences (RNA) 10-K2024 FY Annual report

Filed: 27 Feb 25, 4:13pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. junior Avg

New words: abdominal, acute, adolescent, Agameee, Agamree, ambulatory, ankle, archived, ASO, ASP, baseline, belief, beneficiary, Bio, Bioscience, birth, braxlosiran, Catalyst, ceiling, Celularity, CHMP, circumstance, CK, clinician, clock, Coast, concretely, conspiracy, construction, Council, CSF, CTA, CTR, deceptive, Delpacibart, destruction, disorder, disproportionate, Distinguishing, DOD, dorsiflexion, Duvyzat, elbow, ester, etedesiran, ethical, evolution, FCP, feedback, flexion, formula, formulary, FORTITUDETM, freestanding, FSS, Gamma, GenAhead, Genethon, GMP, Guard, HDAC, headquartered, Hedging, Helsinki, homeobox, HRSA, inaccurate, Inspector, instrument, Intercompany, intermediate, interstate, issuable, Italfarmaco, Kate, knee, limb, logo, MAA, maker, marker, MDA, MDRP, microdystrophin, mouth, nausea, notably, OLE, outer, overcharge, oxidative, PD, phospholamban, PK, PLN, portal, practitioner, principle, procurement, profound, PSU, radiographic, reachable, reauthorized, recalculation, refund, regime, remarkable, repaid, resident, Retail, retention, RNAi, rural, RWS, salt, shock, shoulder, Simona, Skerjanec, standing, statutorily, sublandlord, sublease, subunit, sunset, supplier, suppression, syndrome, TD, tenant, thought, translation, transmission, unadjusted, untimely, VA, variation, verity, Vice, VILTEPSO, voucher, wholesale, workspace, zotadirsen

Removed: adjust, adulthood, advice, assembled, breathe, bundled, climbing, clinic, closed, commencing, complicate, conjugating, CPRA, customary, degradation, developmental, dosed, dramatically, earn, ease, eleven, embedded, employ, equimolar, Fargo, fold, Fourteen, Fulcrum, gathered, half, histopathologic, impacting, implanted, infrequently, infused, inhaled, inhibition, injected, Inline, inspectional, instilled, intact, interactive, juncture, Justice, lab, Leerink, losmapimod, manifest, MAPK, mdx, medium, neck, neurological, NHP, nM, NOAEL, noncompetitive, notified, optimization, panel, paralyzed, partnered, pelvic, Pfizer, plasma, PPMO, progressing, realization, recognizing, resumed, satisfying, settle, Shield, silencing, stable, suffering, suggest, Suisse, SVB, tolerated, traceability, tract, uncured, unsecured, ventilator, vision, walk, wholly, widely, worked, XBRL

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

RNA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the annual report of Avidity Biosciences, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael F. MacLean, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: February 27, 2025			/s/ Michael F. MacLean
			Michael F. MacLean
			Chief Financial and Chief Business Officer (Principal Financial Officer)

The foregoing certification is being furnished solely pursuant to 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.